ProfileGDS5678 / 1422053_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 74% 75% 73% 76% 77% 75% 74% 74% 77% 77% 76% 78% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0379276
GSM967853U87-EV human glioblastoma xenograft - Control 24.8875474
GSM967854U87-EV human glioblastoma xenograft - Control 35.0311975
GSM967855U87-EV human glioblastoma xenograft - Control 44.851873
GSM967856U87-EV human glioblastoma xenograft - Control 55.1650476
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1073277
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.877575
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8593174
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.8641174
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.3088777
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.2068177
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.0997476
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.374178
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.2213677